Guangdong Lewwin Pharmaceutical purchases Provantis Preclinical software solution suite

IT solutions to the global life sciences market, Instem announces the purchase of  Provantis preclinical software solution suite by  Guangdong Lewwin Pharmaceutical Research Institute in order to manage preclinical processes at the Center for Drug Non-clinical Evaluation and Research of Guangdong Institute of Applied Biological Resources in Guangdong, Southern China. Claimed to be the first institute to secure the full CFDA GLP certificate (9 items) and has also achieved AAALAC international certification in the field of non-clinical safety evaluation pharmacology, toxicology, new drug screening research and cellular biology research. Provantis assures to comply with GLP regulatory exemplifying efficient collection, storage, and reporting of preclinical data.

Dr. Wei Yang, Director of the Center said “When evaluating the systems available on the market it was very important for us to hear first-hand experiences from current users and to see the software in action. Members of our team undertook extended visits to two of Instem’s existing clients in the region and we were very impressed with the software functionality, ease of use and the efficiency gains Provantis is delivering within these organizations.”